1
|
Kiefer D, Schneider L, Braun J, Kiltz U, Kolle N, Andreica I, Tsiami S, Buehring B, Sewerin P, Herbold S, Baraliakos X. Clinically relevant differences in spinal mobility related to daytime performance in patients with axial spondyloarthritis. RMD Open 2024; 10:e003733. [PMID: 38191214 PMCID: PMC10806495 DOI: 10.1136/rmdopen-2023-003733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2023] [Accepted: 11/30/2023] [Indexed: 01/10/2024] Open
Abstract
OBJECTIVE Patients with axial spondyloarthritis (axSpA) suffer from clinical symptoms like morning stiffness and back pain. Mobility of patients with axSpA is often impaired. The aim of this study is to compare the performance of patients with axSpA regarding mobility measures including performance-based tests and objective electronic assessments with the Epionics SPINE device (ES) at different times of the day compared with healthy controls (HC). METHODS Observational trial, consecutive inpatients with axSpA (n=100) and 20 HCs were examined in the morning (V1: before 10:00 am) and in the afternoon (V2: after 02:00 pm) by the Bath Ankylosing Spondylitis Metrology Index (BASMI), the AS physical performance index (ASPI), the Short Physical Performance Battery (SPPB) and ES measurements, including range of motion (RoM) and range of kinematics (RoK). RESULTS The assessments of patients with axSpA performed in the morning clearly differed from those in the afternoon, especially regarding performance-based tests. Significant improvements were seen for BASMI (4.0±3.8 to 3.8±1.9; p<0.001), ASPI (36.2±18.3 to 28.8±11.9 s; p<0.001), SPPB (10.1±1.5 to 10.7±1.4 points; p<0.001) and for ES measures of speed (RoK; p<0.018) but not for RoM, except for lateral flexion (13.3±7.4 to 14.7±8.2°; p=0.002). This time of assessment-related variability was not observed in HC. CONCLUSION The spinal mobility of patients with axSpA was worse in the morning but significantly improved in the afternoon. This was captured best by performance-based measures and was not seen in HC. The diurnal variation of mobility has implications for clinical studies, suggesting that the time of assessments needs to be standardised.
Collapse
Affiliation(s)
- David Kiefer
- Rheumatologie, Ruhr-Universitat Bochum, Bochum, Germany
- Rheumatologie, Rheumazentrum Ruhrgebiet, Herne, NRW, Germany
| | - Lucia Schneider
- Ruhr University Bochum, Bochum, Nordrhein-Westfalen, Germany
| | - Jürgen Braun
- Ruhr University Bochum, Bochum, Nordrhein-Westfalen, Germany
| | - Uta Kiltz
- Ruhr University Bochum, Bochum, Nordrhein-Westfalen, Germany
- Rheumazentrum Ruhrgebiet, Herne, Nordrhein-Westfalen, Germany
| | - Niklas Kolle
- Ruhr University Bochum, Bochum, Nordrhein-Westfalen, Germany
| | - Ioana Andreica
- Ruhr University Bochum, Bochum, Nordrhein-Westfalen, Germany
- Rheumazentrum Ruhrgebiet, Herne, Nordrhein-Westfalen, Germany
| | - Styliani Tsiami
- Rheumazentrum Ruhrgebiet, Herne, Nordrhein-Westfalen, Germany
- Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany
| | | | - Philipp Sewerin
- Ruhr University Bochum, Bochum, Nordrhein-Westfalen, Germany
| | - Susanne Herbold
- Ruhr University Bochum, Bochum, Nordrhein-Westfalen, Germany
| | | |
Collapse
|
2
|
Kiefer D, Baraliakos X, Adolf D, Chatzistefanidi V, Schwarze I, Lange U, Brandt-Jürgens J, Stemmler E, Sartingen S, Braun J. Successful evaluation of spinal mobility measurements with the Epionics SPINE device in patients with axial spondyloarthritis compared to controls. J Rheumatol 2021; 49:44-52. [PMID: 34393107 DOI: 10.3899/jrheum.201470] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/03/2021] [Indexed: 11/22/2022]
Abstract
OBJECTIVE To evaluate ES for quantification of spinal mobility in patients with axSpA. METHODS A total of 153 individuals, 39 females and 114 males, were examined:134 axSpA patients, 40 non-(nr-) and 94 radiographic (r)-axSpA, and 19 healthy controls (HC), respectively. The results were compared using mean ES scores and modeling was performed using multivariable logistic regression models resulting in good validity and high discriminative power. RESULTS ES measurements showed meaningful differences between axSpA patients and HC (all p<0.001) as well as between r- and nr-axSpA (p<0.01). In axSpA patients a negative correlation between ES and BASMI values was found: -0.76≤r≤-0.52 (p<0.05). BASFI scores showed a similar trend (r > -0.39). Patients with r-axSpA had a more limited and slower spinal mobility than those with nr-axSpA. Other patient reported outcomes did almost not correlate. CONCLUSION This study shows that the ES is an objective performance measure and a valid tool to assess spinal mobility in axSpA, also based on OMERACT criteria. RoK and RoM scores provide additional information on physical function of axSpA patients.
Collapse
Affiliation(s)
- David Kiefer
- Rheumazentrum Ruhrgebiet, Ruhr-University Bochum; StatConsult, Gesellschaft für klinische und Versorgungsforschung mbH Magdeburg, Germany; Praxis für Rheumatologie, Leipzig; Rheumatologie und klinische Immunologie Campus Kerckhoff, Bad Nauheim, Universität Gießen; Rheumatologische Schwerpunktpraxis, Berlin; Medical Immunology, AbbVie Deutschland GmbH & Co. KG, Germany. AbbVie sponsored this study and contributed to the design, study conduct, and analysis. AbbVie participated in the interpretation of data, review, and approval of the Manuscript. D. Kiefer, X. Baraliakos, D. Adolf, V. Chatzistefanidi, I. Schwarze, U. Lange, J. Brandt-Jürgens, and J. Braun received speaker or consulting fees from AbbVie. E. Stemmler, and S. Sartingen are employees of AbbVie and may own AbbVie stock. AbbVie sponsored this study and contributed to the design, study conduct, and analysis. AbbVie participated in the interpretation of data, review, and approval of the Manuscript. Corresponding author: David Kiefer, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Claudiusstrasse 45, 44649 Herne, Germany.
| | - Xenofon Baraliakos
- Rheumazentrum Ruhrgebiet, Ruhr-University Bochum; StatConsult, Gesellschaft für klinische und Versorgungsforschung mbH Magdeburg, Germany; Praxis für Rheumatologie, Leipzig; Rheumatologie und klinische Immunologie Campus Kerckhoff, Bad Nauheim, Universität Gießen; Rheumatologische Schwerpunktpraxis, Berlin; Medical Immunology, AbbVie Deutschland GmbH & Co. KG, Germany. AbbVie sponsored this study and contributed to the design, study conduct, and analysis. AbbVie participated in the interpretation of data, review, and approval of the Manuscript. D. Kiefer, X. Baraliakos, D. Adolf, V. Chatzistefanidi, I. Schwarze, U. Lange, J. Brandt-Jürgens, and J. Braun received speaker or consulting fees from AbbVie. E. Stemmler, and S. Sartingen are employees of AbbVie and may own AbbVie stock. AbbVie sponsored this study and contributed to the design, study conduct, and analysis. AbbVie participated in the interpretation of data, review, and approval of the Manuscript. Corresponding author: David Kiefer, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Claudiusstrasse 45, 44649 Herne, Germany.
| | - Daniela Adolf
- Rheumazentrum Ruhrgebiet, Ruhr-University Bochum; StatConsult, Gesellschaft für klinische und Versorgungsforschung mbH Magdeburg, Germany; Praxis für Rheumatologie, Leipzig; Rheumatologie und klinische Immunologie Campus Kerckhoff, Bad Nauheim, Universität Gießen; Rheumatologische Schwerpunktpraxis, Berlin; Medical Immunology, AbbVie Deutschland GmbH & Co. KG, Germany. AbbVie sponsored this study and contributed to the design, study conduct, and analysis. AbbVie participated in the interpretation of data, review, and approval of the Manuscript. D. Kiefer, X. Baraliakos, D. Adolf, V. Chatzistefanidi, I. Schwarze, U. Lange, J. Brandt-Jürgens, and J. Braun received speaker or consulting fees from AbbVie. E. Stemmler, and S. Sartingen are employees of AbbVie and may own AbbVie stock. AbbVie sponsored this study and contributed to the design, study conduct, and analysis. AbbVie participated in the interpretation of data, review, and approval of the Manuscript. Corresponding author: David Kiefer, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Claudiusstrasse 45, 44649 Herne, Germany.
| | - Varvara Chatzistefanidi
- Rheumazentrum Ruhrgebiet, Ruhr-University Bochum; StatConsult, Gesellschaft für klinische und Versorgungsforschung mbH Magdeburg, Germany; Praxis für Rheumatologie, Leipzig; Rheumatologie und klinische Immunologie Campus Kerckhoff, Bad Nauheim, Universität Gießen; Rheumatologische Schwerpunktpraxis, Berlin; Medical Immunology, AbbVie Deutschland GmbH & Co. KG, Germany. AbbVie sponsored this study and contributed to the design, study conduct, and analysis. AbbVie participated in the interpretation of data, review, and approval of the Manuscript. D. Kiefer, X. Baraliakos, D. Adolf, V. Chatzistefanidi, I. Schwarze, U. Lange, J. Brandt-Jürgens, and J. Braun received speaker or consulting fees from AbbVie. E. Stemmler, and S. Sartingen are employees of AbbVie and may own AbbVie stock. AbbVie sponsored this study and contributed to the design, study conduct, and analysis. AbbVie participated in the interpretation of data, review, and approval of the Manuscript. Corresponding author: David Kiefer, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Claudiusstrasse 45, 44649 Herne, Germany.
| | - Ilka Schwarze
- Rheumazentrum Ruhrgebiet, Ruhr-University Bochum; StatConsult, Gesellschaft für klinische und Versorgungsforschung mbH Magdeburg, Germany; Praxis für Rheumatologie, Leipzig; Rheumatologie und klinische Immunologie Campus Kerckhoff, Bad Nauheim, Universität Gießen; Rheumatologische Schwerpunktpraxis, Berlin; Medical Immunology, AbbVie Deutschland GmbH & Co. KG, Germany. AbbVie sponsored this study and contributed to the design, study conduct, and analysis. AbbVie participated in the interpretation of data, review, and approval of the Manuscript. D. Kiefer, X. Baraliakos, D. Adolf, V. Chatzistefanidi, I. Schwarze, U. Lange, J. Brandt-Jürgens, and J. Braun received speaker or consulting fees from AbbVie. E. Stemmler, and S. Sartingen are employees of AbbVie and may own AbbVie stock. AbbVie sponsored this study and contributed to the design, study conduct, and analysis. AbbVie participated in the interpretation of data, review, and approval of the Manuscript. Corresponding author: David Kiefer, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Claudiusstrasse 45, 44649 Herne, Germany.
| | - Uwe Lange
- Rheumazentrum Ruhrgebiet, Ruhr-University Bochum; StatConsult, Gesellschaft für klinische und Versorgungsforschung mbH Magdeburg, Germany; Praxis für Rheumatologie, Leipzig; Rheumatologie und klinische Immunologie Campus Kerckhoff, Bad Nauheim, Universität Gießen; Rheumatologische Schwerpunktpraxis, Berlin; Medical Immunology, AbbVie Deutschland GmbH & Co. KG, Germany. AbbVie sponsored this study and contributed to the design, study conduct, and analysis. AbbVie participated in the interpretation of data, review, and approval of the Manuscript. D. Kiefer, X. Baraliakos, D. Adolf, V. Chatzistefanidi, I. Schwarze, U. Lange, J. Brandt-Jürgens, and J. Braun received speaker or consulting fees from AbbVie. E. Stemmler, and S. Sartingen are employees of AbbVie and may own AbbVie stock. AbbVie sponsored this study and contributed to the design, study conduct, and analysis. AbbVie participated in the interpretation of data, review, and approval of the Manuscript. Corresponding author: David Kiefer, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Claudiusstrasse 45, 44649 Herne, Germany.
| | - Jan Brandt-Jürgens
- Rheumazentrum Ruhrgebiet, Ruhr-University Bochum; StatConsult, Gesellschaft für klinische und Versorgungsforschung mbH Magdeburg, Germany; Praxis für Rheumatologie, Leipzig; Rheumatologie und klinische Immunologie Campus Kerckhoff, Bad Nauheim, Universität Gießen; Rheumatologische Schwerpunktpraxis, Berlin; Medical Immunology, AbbVie Deutschland GmbH & Co. KG, Germany. AbbVie sponsored this study and contributed to the design, study conduct, and analysis. AbbVie participated in the interpretation of data, review, and approval of the Manuscript. D. Kiefer, X. Baraliakos, D. Adolf, V. Chatzistefanidi, I. Schwarze, U. Lange, J. Brandt-Jürgens, and J. Braun received speaker or consulting fees from AbbVie. E. Stemmler, and S. Sartingen are employees of AbbVie and may own AbbVie stock. AbbVie sponsored this study and contributed to the design, study conduct, and analysis. AbbVie participated in the interpretation of data, review, and approval of the Manuscript. Corresponding author: David Kiefer, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Claudiusstrasse 45, 44649 Herne, Germany.
| | - Edgar Stemmler
- Rheumazentrum Ruhrgebiet, Ruhr-University Bochum; StatConsult, Gesellschaft für klinische und Versorgungsforschung mbH Magdeburg, Germany; Praxis für Rheumatologie, Leipzig; Rheumatologie und klinische Immunologie Campus Kerckhoff, Bad Nauheim, Universität Gießen; Rheumatologische Schwerpunktpraxis, Berlin; Medical Immunology, AbbVie Deutschland GmbH & Co. KG, Germany. AbbVie sponsored this study and contributed to the design, study conduct, and analysis. AbbVie participated in the interpretation of data, review, and approval of the Manuscript. D. Kiefer, X. Baraliakos, D. Adolf, V. Chatzistefanidi, I. Schwarze, U. Lange, J. Brandt-Jürgens, and J. Braun received speaker or consulting fees from AbbVie. E. Stemmler, and S. Sartingen are employees of AbbVie and may own AbbVie stock. AbbVie sponsored this study and contributed to the design, study conduct, and analysis. AbbVie participated in the interpretation of data, review, and approval of the Manuscript. Corresponding author: David Kiefer, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Claudiusstrasse 45, 44649 Herne, Germany.
| | - Sabine Sartingen
- Rheumazentrum Ruhrgebiet, Ruhr-University Bochum; StatConsult, Gesellschaft für klinische und Versorgungsforschung mbH Magdeburg, Germany; Praxis für Rheumatologie, Leipzig; Rheumatologie und klinische Immunologie Campus Kerckhoff, Bad Nauheim, Universität Gießen; Rheumatologische Schwerpunktpraxis, Berlin; Medical Immunology, AbbVie Deutschland GmbH & Co. KG, Germany. AbbVie sponsored this study and contributed to the design, study conduct, and analysis. AbbVie participated in the interpretation of data, review, and approval of the Manuscript. D. Kiefer, X. Baraliakos, D. Adolf, V. Chatzistefanidi, I. Schwarze, U. Lange, J. Brandt-Jürgens, and J. Braun received speaker or consulting fees from AbbVie. E. Stemmler, and S. Sartingen are employees of AbbVie and may own AbbVie stock. AbbVie sponsored this study and contributed to the design, study conduct, and analysis. AbbVie participated in the interpretation of data, review, and approval of the Manuscript. Corresponding author: David Kiefer, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Claudiusstrasse 45, 44649 Herne, Germany.
| | - Jürgen Braun
- Rheumazentrum Ruhrgebiet, Ruhr-University Bochum; StatConsult, Gesellschaft für klinische und Versorgungsforschung mbH Magdeburg, Germany; Praxis für Rheumatologie, Leipzig; Rheumatologie und klinische Immunologie Campus Kerckhoff, Bad Nauheim, Universität Gießen; Rheumatologische Schwerpunktpraxis, Berlin; Medical Immunology, AbbVie Deutschland GmbH & Co. KG, Germany. AbbVie sponsored this study and contributed to the design, study conduct, and analysis. AbbVie participated in the interpretation of data, review, and approval of the Manuscript. D. Kiefer, X. Baraliakos, D. Adolf, V. Chatzistefanidi, I. Schwarze, U. Lange, J. Brandt-Jürgens, and J. Braun received speaker or consulting fees from AbbVie. E. Stemmler, and S. Sartingen are employees of AbbVie and may own AbbVie stock. AbbVie sponsored this study and contributed to the design, study conduct, and analysis. AbbVie participated in the interpretation of data, review, and approval of the Manuscript. Corresponding author: David Kiefer, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Claudiusstrasse 45, 44649 Herne, Germany.
| |
Collapse
|